Back to search results
NCT06648785

Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies

Enrolling by Invitation
PHASE2Ages 18+InterventionalTreatment
University of Vermont Medical Center
~20 participants
Updated 2026-02-05 on ClinicalTrials.gov
What's tested:oxaliplatinFluoropyrimidine

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Tolerability
Measured over 115 days
+3 more outcomes measured

Conditions

GI Cancers

Explore related trials

Gastrointestinal Malignancies

Where it's being run

2 sites across 1 states
Vermont2

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient with GI malignancy
Provider plans non-curative intent treatment with either CAPOX or FOLFOX (mFOLFOX6) at standard dosages for \>3 months NOTE: Patient is not required to have radiologically measurable disease. NOTE: Planned administration of other anti-cancer medications (eg bevacizumab, epidermal growth factor receptor antibodies, immunotherapy, tyrosine kinase inhibitors) is allowed.

Exclusion

Patients not meeting standard hematologic parameters for chemotherapy administration as follows:
Absolute neutrophil count (ANC) ≥ 1500
Platelet count ≥ 100,000 Patients not meeting standard liver function parameters for chemotherapy administration as follows:
AST ≤ 5x ULN
ALT ≤ 5X ULN
Total Bilirubin ≤ 1.5X ULN Patients not meeting standard renal function parameters for chemotherapy administration as follows:
Serum Creatinine ≤ 1.2 or creatinine clearance ≥ 30 ml/min NOTE: Planned administration of another cytotoxic chemotherapy (eg irinotecan) is an exclusion.

What this trial measures

  • Tolerability115 days

    Number of toxicity-related treatment delays Number of dose reductions

  • Toxicity115 days

    Severity of acute oxaliplatin reactions, graded 1-4

  • Neuropathy2-4 months after therapy

    Neuropathy will be graded 1-4 after 2 \&4 months of severity

  • Cytopenias115 days

    Frequency of cytopenia grade 3 or higher.